Personalized Hydration Strategy for Acute Kidney Injury
(NEPTUNE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new personalized hydration strategy to prevent kidney problems that might occur after certain heart procedures. The researchers aim to determine if adjusting fluid levels based on specific heart and kidney functions can prevent kidney injury caused by contrast dyes used in these procedures. Participants will receive either this new hydration method or standard care, which may include treatments like botulinum toxin injections, anticholinergics, baclofen, levodopa, or deep brain stimulation. Individuals planning to undergo a coronary angiogram or PCI and willing to participate might be a good fit for this trial.
As an unphased trial, this study offers participants the chance to contribute to innovative research that could improve future heart procedure outcomes.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this personalized hydration strategy is safe for preventing acute kidney injury?
Research has shown that a personalized hydration plan is generally safe and does not significantly increase the risk of pulmonary edema, a condition that makes breathing difficult. This plan adjusts fluid amounts based on specific heart and kidney measurements. Studies have found it to be a safe and effective way to prevent kidney problems during procedures like coronary angiograms. Overall, this method is well-tolerated and does not appear to cause major issues.12345
Why are researchers excited about this trial?
Researchers are excited about the personalized hydration strategy for acute kidney injury because it tailors fluid administration based on individual patient needs, unlike the standard one-size-fits-all approach. This strategy adjusts the infusion rate by considering factors like left ventricular end-diastolic pressure (LVEDP) and the ratio of contrast volume to estimated glomerular filtration rate (eGFR), making it more precise. By customizing hydration, the treatment aims to optimize kidney function and potentially reduce complications, which is a significant improvement over the current standard of care that uses a fixed infusion rate.
What evidence suggests that this trial's treatments could be effective for preventing contrast-induced acute kidney injury?
This trial will compare a personalized hydration strategy with standard care to prevent kidney problems after heart procedures like angiograms. Research has shown that a personalized hydration plan might help prevent kidney issues. One study found that adjusting hydration based on heart pressure appeared promising but did not significantly reduce kidney problems in individuals with chronic kidney disease. Another study revealed that patients often did not receive their full hydration dose, potentially affecting the results. Some evidence suggests that guiding hydration by urine flow rate might be effective and safe. Overall, this approach appears promising but requires more evidence to confirm its effectiveness.13456
Who Is on the Research Team?
Guillaume Marquis-Gravel, MD
Principal Investigator
Montreal Heart Institute
Are You a Good Fit for This Trial?
This trial is for adults over 18 who are about to have a heart procedure like coronary angiogram or PCI and can attend follow-up visits. They should expect to live at least 6 more months. It's not for those in shock, having emergency procedures, recent contrast media exposure, severe heart valve disease, very weak hearts (LVEF <30%), or current kidney issues.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a personalized or standard hydration strategy during and after coronary angiogram and/or PCI
Follow-up
Participants are monitored for safety and effectiveness after treatment, with serum creatinine measured at 48 hours, 7 days, and 6 months
What Are the Treatments Tested in This Trial?
Interventions
- Personalized hydration strategy
- Standard of care
Find a Clinic Near You
Who Is Running the Clinical Trial?
Guillaume Marquis-Gravel
Lead Sponsor
Montreal Heart Institute
Lead Sponsor
Université de Montréal
Collaborator
Canadian Institutes of Health Research (CIHR)
Collaborator